Chronic lymphocytic leukaemia Australasian consensus practice statement
Mary Ann Anderson(The Royal Melbourne Hospital), Stephen P. Mulligan(Royal North Shore Hospital), Bryone J. Kuss(Flinders Medical Centre), Giles Best(Flinders University), Joel Wight(Townsville Hospital), Rosemary Harrup(University of Tasmania), Kyle Crassini(Coffs Harbour City Council), Sumita Ratnasingam(Monash Health), Constantine S. Tam(The Alfred Hospital), Tara Cochrane(Gold Coast Hospital), Rory Bennett(The Royal Melbourne Hospital), Nicole Chia(Alexandra Hospital), Dipti Talaulikar(Australian National University), Emma Palfreyman(Royal Darwin Hospital), Mark N. Polizzotto(AIDS United), Sharon Jackson(University of Leeds), Paula Marlton(The University of Queensland), Asha Soosapilla, John F. Seymour(The Royal Melbourne Hospital), Masa Lasica(St Vincent's Hospital Melbourne), Xavier C. Badoux(St George Hospital), Stephen Opat(Monash Health), Robert Weinkove(Malaghan Institute of Medical Research), Thomas E. Lew(The Royal Melbourne Hospital), Gavin Cull(Sir Charles Gairdner Hospital)
Cited by 12
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k